DZD Awarded SBIR Grant for Development of Microbiome Diagnostics
August 29 2023
This award funds DZD's development of epiXact®FMT, a pharmacovigilance assay to enhance safety and efficacy in fecal microbiota transplant (FMT) clinical trials.
Read More
DZD Welcomes Healthcare Business Leader Gail Marcus to its Board
November 9 2022
DZD announced that Gail Marcus has joined the company’s Board of Directors as an independent director
Read More
DZD Awarded $8.2 Million in Additional CARB-X Funding To Support Ongoing Development of its Infectious Disease Rapid Diagnostic
October 20 2022
DZD Will Continue Clinical Validation and Product Engineering of its Novel Technology Designed to Reduce Time to Diagnosis from Days to Hours
Read More
Molecular Diagnostics Experts Added to Advisory Board
August 25 2022
Dr. Amy Mathers and Rob Crisp Bring Extensive Academic and Industry Experience
Read More
Day Zero Diagnostics Announces the Launch of Day Zero Lab Services
April 8 2022
Providing Whole Genome Sequencing Based Services for High Impact Clinical Decisions
Read More
Day Zero Diagnostics Announces Completion of $21M Financing
February 8 2022
Funding development of a disruptive whole-genome sequencing-based diagnostic system for bloodstream infections
Read More